Clear Harbor Asset Management LLC Decreases Stake in AbbVie Inc. $ABBV

Clear Harbor Asset Management LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 7.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,583 shares of the company’s stock after selling 2,797 shares during the period. Clear Harbor Asset Management LLC’s holdings in AbbVie were worth $7,776,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie in the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. purchased a new position in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the second quarter valued at $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie during the 2nd quarter worth about $36,000. Finally, Delos Wealth Advisors LLC acquired a new position in shares of AbbVie during the 2nd quarter worth about $39,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline/clinical progress — AbbVie advanced its icalcaprant (depression) Phase 2 program, which supports medium‑term pipeline optionality beyond its core immunology/oncology franchises. AbbVie Advances Icalcaprant Trial in Depression: What Investors Should Watch
• Positive Sentiment: Early‑stage oncology expansion — AbbVie launched a first‑in‑human trial for ABBV‑901 in ovarian cancer, increasing optional upside if the program shows early signal. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Positive Sentiment: Analyst support — Berenberg issued a buy on ABBV, giving some near‑term credibility to upside narratives and providing a buy signal for income/value investors. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Dividend/income appeal — commentary highlighting AbbVie’s yield and steady dividend profile is keeping income‑focused investors engaged despite valuation premium. AbbVie: The Dividend Does Not Lie
• Neutral Sentiment: Real‑world study readouts — post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped, which may gradually support label expansion and payer confidence but are not immediate revenue catalysts. AbbVie’s Korean Rinvoq Study in IBD Wraps Up, Setting the Stage for New Real‑World Data
• Neutral Sentiment: Upcoming results call — AbbVie set its full‑year and Q4 earnings release and Feb. 4 conference call; investors will watch guidance reconciliation and quarterly details for clarity. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Negative Sentiment: Guidance slightly below consensus — AbbVie trimmed/updated Q4 and FY‑2025 EPS ranges that sit at or just below street consensus, which likely pressured the stock as investors reprice near‑term growth expectations.
• Negative Sentiment: One‑time IPR&D/R&D charges — management flagged IPR&D and related expenses that will negatively impact Q4 EPS, creating near‑term earnings noise ahead of the February print. AbbVie sees negative Q4 EPS impact from IPR&D expenses
• Negative Sentiment: Failed takeover optimism — earlier media reports that AbbVie was in talks to buy Revolution Medicines briefly lifted sentiment; AbbVie subsequently denied talks, prompting disappointment and a reversal in momentum. AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

AbbVie Trading Down 3.9%

ABBV stock opened at $224.22 on Friday. The company has a market capitalization of $396.28 billion, a P/E ratio of 169.86, a PEG ratio of 0.98 and a beta of 0.36. The business has a 50 day simple moving average of $226.55 and a 200-day simple moving average of $214.86. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ABBV shares. Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Finally, Morgan Stanley increased their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.